Dennis Idowu, M.D., Katrina Merrion, M.S., Nina Wemmer, M.S., Janine Gessner Mash, M.S., Barbara Pettersen, M.S., Dusan Kijacic, M.S., Ruth B. Lathi, M.D.
Volume 103, Issue 4, Pages 1037-1042
To report live birth rates (LBR) and total aneuploidy rates in a series of patients with balanced translocations who pursued in vitro fertilization (IVF)–preimplantation genetic diagnosis (PGD) cycles.
Retrospective cohort analysis.
Genetic testing reference laboratory.
Seventy-four couples who underwent IVF-PGD due to a parental translocation.
IVF cycles and embryo biopsies were performed by referring clinics. Biopsy samples were sent to a single reference lab for PGD for the translocation plus 24-chromosome aneuploidy screening with the use of a single-nucleotide polymorphism (SNP) microarray.
Main Outcome Measure(s):
LBR per biopsy cycle, aneuploidy rate, embryo transfer (ET) rate, miscarriage rate.
The LBR per IVF biopsy cycle was 38%. LBR for patients reaching ET was 52%. Clinical miscarriage rate was 10%. Despite a mean age of 33.8 years and mean of 7 embryos biopsied, there was a 30% chance for no chromosomally normal embryos. Maternal age >35 years, day 3 biopsy, and having fewer than five embryos available for biopsy increased the risk of no ET.
IVF-PGD for translocation and aneuploidy screening had good clinical outcomes. Patients carrying a balanced translocation who are considering IVF-PGD should be aware of the high risk of no ET, particularly in women ≥35 years old.
Read the full text at: http://www.fertstert.org/article/S0015-0282(14)02549-7/fulltext